Zsuzsanna Zsengeller | Medicine and Dentistry | Best Researcher Award

Published on by Phenomenological Research Awards

Dr. Zsuzsanna Zsengeller | Medicine and Dentistry | Best Researcher Award 

Assistant professor at Beth Israel Deaconess Medical Center | United States

Dr. Zsuzsanna Zsengeller is a distinguished medical scientist whose career spans clinical medicine, molecular biology, and translational research. She has established herself as a global leader in the investigation of preeclampsia, mitochondrial dysfunction, and kidney-related disorders. With appointments at world-renowned institutions, she has advanced knowledge in gene therapy, molecular signaling, and maternal-fetal health. Her professional journey demonstrates a seamless integration of clinical insight and laboratory research, producing innovative therapeutic approaches. Through consistent scholarly output, grant leadership, and mentorship of future scientists, Dr. Zsuzsanna Zsengeller embodies excellence in academic medicine and translational science, with her work directly impacting patient health worldwide.

Profile:

Orcid

Education:

Dr. Zsuzsanna Zsengeller earned her Doctor of Medicine degree in General Medicine, followed by a Ph.D. in Medical Science with a strong foundation in microbiology. Her academic path was marked by a commitment to understanding complex disease mechanisms through both experimental and clinical approaches. Her postgraduate training included prestigious postdoctoral fellowships in pulmonary biology and respiratory diseases, where she refined her expertise in molecular and cellular biology. These academic experiences provided the groundwork for her lifelong research into oxidative stress, immune signaling, and vascular biology, ultimately shaping her into a well-recognized expert in mitochondrial and maternal health research.

Experience:

Dr. Zsuzsanna Zsengeller has extensive experience as both a clinician and scientist, having held positions across leading hospitals, research institutions, and industry collaborations. Her work includes significant contributions to pulmonary biology, renal pathology, and preeclampsia research. She has served in roles as staff scientist, senior scientist, consultant, and academic faculty member, currently serving as Assistant Professor of Medicine at Harvard Medical School. Her collaborations with multidisciplinary teams have resulted in advancements in therapeutic strategies for cardiovascular, renal, and maternal health. With experience in academia, industry, and clinical translation, she has built a unique career that bridges discovery and application.

Research Interest:

Dr. Zsuzsanna Zsengeller’s research interests center on the pathogenesis and treatment of preeclampsia, kidney disease, and mitochondrial dysfunction. She investigates redox biology, nitric oxide modulation, and oxidative stress pathways to understand how cellular signaling impacts maternal and fetal outcomes. Her translational studies have examined novel dual-function redox modulators, antioxidants, and mitochondrial-targeted therapies. Beyond maternal health, her work extends into nephrology and cardiovascular disease, with particular focus on mechanisms of APOL nephropathy and endothelial dysfunction. Through advanced molecular techniques and therapeutic modeling, her research seeks to translate laboratory discoveries into clinical strategies, offering hope for improved patient outcomes worldwide.

Awards and Honors:

Dr. Zsuzsanna Zsengeller has been recognized with numerous honors that reflect her leadership in biomedical science and translational medicine. She has received institutional research funding awards, including competitive support for her pioneering work on mitochondrial-targeted antioxidants for preeclampsia therapy. Her contributions have also been acknowledged through awards from scientific societies, highlighting her excellence in poster presentations, mentorship, and innovative project design. Her research projects have consistently received funding from federal agencies and medical foundations, underscoring the clinical relevance and impact of her work. These awards honor her as a trailblazer in developing therapies addressing urgent global health challenges.

Publications:

Title: Development of Diaryl Hydrazones for Alleviation of Mitochondrial Oxidative Stress in Preeclampsia
Year of Publication: 2025
Citation: 1

Title: Gasdermin D deletion prevents liver injury and exacerbates extrahepatic damage in a murine model of alcohol-induced ACLF
Year of Publication: 2025
Citation: 1

Title: A Novel Multi-organ Male Model of Alcohol-induced Acute-on-chronic Liver Failure Reveals NET-mediated Hepatocellular Death, Which is Prevented by RIPK3 Inhibition
Year of Publication: 2025
Citation: 5

Title: Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2
Year of Publication: 2024
Citation: 5

Title: Solvent- and Catalyst-Free Environmentally Benign High Hydrostatic Pressure-Assisted Synthesis of Bioactive Hydrazones and the Evaluation of Their Stability Under Various Storage Conditions
Year of Publication: 2024
Citation: 3

Title: A Novel Dual-Function Nitric Oxide Donor Therapy for Preeclampsia—A Proof-of-Principle Study in a Murine Model
Year of Publication: 2023
Citation: 3

Title: Hepatocyte nuclear factor 4α mediated quinolinate phosphoribosylltransferase (QPRT) expression in the kidney facilitates resilience against acute kidney injury
Year of Publication: 2023
Citation: 8

Conclusion:

Dr. Zsuzsanna  Zsengeller stands as a pioneering physician-scientist whose research has transformed the understanding of oxidative stress, mitochondrial dysfunction, and maternal-fetal disorders. Her leadership in translational medicine continues to advance new therapies that address major public health burdens, particularly preeclampsia and kidney disease. Through groundbreaking research, impactful publications, and mentorship of future leaders, she exemplifies the highest standards of academic and clinical excellence. Her career demonstrates how dedication to discovery can be translated into real-world medical advancements, making her a highly deserving candidate for prestigious recognition in biomedical and clinical research innovation.

Nazanin mahinparvar | Medicine | Best Researcher Award

Published on by Phenomenological Research Awards

Nazanin mahinparvar | Medicine | Best Researcher Award

Postdoc at Stanford university, United States.

Dr. Nazanin Mahinparvar is a postdoctoral scholar at Stanford University, focusing on bioengineering and pain management. She brings a blend of medical and research expertise to her work, aiming to develop innovative gene therapies that offer non-addictive, effective treatments for chronic pain. Her research in synthetic biology, combined with her clinical background as an emergency medicine physician, underscores her commitment to translating laboratory discoveries into practical healthcare solutions. Throughout her career, she has received numerous accolades for her dedication to patient care and research excellence, including the Best Physician Award during the COVID-19 pandemic. Her approach to research is driven by a patient-centered perspective, making her work both scientifically rigorous and highly relevant to addressing current health challenges. Dr. Mahinparvar’s focus on developing HSV-based biotechnologies has the potential to reshape pain management therapies, positioning her as a significant contributor to advancements in medical science.

Profile👤

Scopus

Education 🎓

Dr. Nazanin Mahinparvar’s educational journey is marked by excellence and a clear dedication to advancing medical knowledge. She began her studies in Biology at SAMPAD in Iran, followed by an MD at Isfahan Medical University, where she was recognized with high honors. Her medical education included an emphasis on pain management, an area she explored further during her mandatory medical service program. Her commitment to lifelong learning and research brought her to Stanford University for a prestigious postdoctoral position in bioengineering. Dr. Mahinparvar’s educational background integrates both foundational medical training and specialized knowledge in synthetic biology and gene therapy. Her academic journey has been marked by a strong interdisciplinary focus, with formal training that spans basic sciences, clinical practice, and cutting-edge bioengineering. This diverse educational foundation provides her with a unique perspective, enabling her to bridge the gap between laboratory research and patient-centered clinical applications.

Experience💼

Dr. Nazanin Mahinparvar has extensive experience in both clinical and research settings, blending hands-on patient care with innovative scientific research. Her early career as a physician involved managing healthcare in underserved areas, where she was honored with the Best Doctor Award for her exceptional patient care. Following this, she served as an emergency medicine physician, honing her ability to operate under pressure. During her postdoctoral work at Stanford, she focused on developing non-toxic HSV-based therapies for chronic pain and neurological disorders. Her clinical experience in pain management, coupled with her research in gene therapy and synthetic biology, has positioned her as a leader in innovative medical research. Dr. Mahinparvar’s experience is a blend of practical and scientific expertise, which she continually refines through collaboration with top scientists and participation in clinical trials. Her background uniquely equips her to drive impactful advancements in pain management and gene-based therapies.

Research Interests 🔬

Dr. Mahinparvar’s research interests focus on engineering advanced, safe, and efficient gene therapies for chronic pain and neurological disorders. She specializes in developing non-addictive pain management treatments using synthetic biology and gene engineering, with a particular interest in non-toxic HSV-based technologies. Dr. Mahinparvar’s work aims to address global health challenges by providing affordable, accessible solutions for conditions that currently lack effective, low-risk treatments. At Stanford’s Wu Tsai Neurosciences Institute, her research delves into combining gene therapy with bioengineering to create precise, targeted interventions. Her early research on selenium’s effects on respiratory functions in ICU patients sparked her interest in translational medicine, which she has expanded to chronic pain and neuro-oncology applications. Dr. Mahinparvar’s research is ultimately driven by her commitment to improving patient outcomes and advancing the field of pain management through innovative, cross-disciplinary approaches that bridge the laboratory and the clinic.

Awards and Honors 🏆

Throughout her career, Dr. Mahinparvar has earned multiple awards recognizing her excellence in both research and clinical practice. In 2021, she received the Best Physician Award for her dedication to patient care during the COVID-19 pandemic, reflecting her commitment to providing quality healthcare under challenging conditions. She was also honored with the Foundation of Future Medical Research Fellowship at the Kheradmand Institute, which brought her to Stanford for advanced research in head and neck surgery and gene therapy. Other accolades include her high-honors MD dissertation award and the Best Student Award from Iran’s SAMPAD organization for exceptional talent. These recognitions highlight Dr. Mahinparvar’s leadership, resilience, and contribution to medicine. Her awards underscore her determination to push the boundaries of traditional pain management, making her a strong candidate for future honors in the fields of bioengineering and clinical research.

Conclusion 🔚 

Dr. Mahinparvar’s academic and clinical achievements, including her innovative work in chronic pain management, place her among the most promising candidates for the Best Researcher Award. Her interdisciplinary research, combined with her commitment to patient care and clinical applications, demonstrates her potential to make lasting contributions to medical science and public health. This award would provide well-deserved recognition and support to advance her impactful research on a global scale.

Publications Top Notes 📚

Title: Oxytocin Receptors on Calvarial Periosteal Innervation: Therapeutic Target for Post-Traumatic Headache?
Authors: Bharadwaj, V.N., Klukinov, M., Cowan, R.P., Mahinparvar, N., Clark, D.J., Yeomans, D.C.
Year: 2024
Journal: Pharmaceutics, 16(6), 760
Citation Count: 0

Title: Chemopreventive and therapeutic potential of curcumin in esophageal cancer: Current and future status
Authors: Hesari, A., Azizian, M., Sheikhi, A., Nesaei, A., Sanaei, S., Mahinparvar, N., Derakhshani, M., Hedayt, P., Ghasemi, F., Mirzaei, H.
Year: 2019
Journal: International Journal of Cancer, 144(6), pp. 1215–1226
Citation Count: 103

Title: Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis
Authors: Etemadifar, M., Ghourchian, S., Mahinparvar, N., Sanaei, S., Akbari, M.
Year: 2019
Journal: Acta Medica Iranica, 57(8), pp. 484–491
Citation Count: 2

Title: Comparison of the efficacy of midazolam and dexmedetomidine in quality of sedation in mechanically-ventilated patients admitted to intensive care unit
Authors: Kashefi, P., Mahinparvar, N., Khalifsoltani-Khajooie, M., Mansouri, P., Sanaei, S.
Year: 2018
Journal: Journal of Isfahan Medical School, 35(460), pp. 1799–1805
Citation Count: 1

Title: The effect of selenium on maximum inspiratory pressure in patients under mechanical ventilation in intensive care units
Authors: Alikiaii, B., Mahinparvar, N.
Year: 2017
Journal: Journal of Isfahan Medical School, 35(423), pp. 291–296
Citation Count: 1